Skip to main content
Caplight Logo









Emmecell

Emmecell

Private
Menlo Park, CaliforniaHealthcare & Life Scienceshttps://www.emmecell.com/

Last Round

Strategic

Jun 16, 2026

Total Funding Raised

$46M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Emmecell is a biotechnology company that develops cell-based therapies for the treatment of eye diseases using its proprietary Magnetic Cell Delivery (MCD) nanoparticle platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Medical Devices

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Non-AI

Keywords

cell therapymagnetic cell deliverycorneal edemaophthalmic therapiesclinical stage biotechregenerative medicineMCD platformnanoparticle deliverycorneal transplant alternativecGMP manufacturingcell therapy CDMOophthalmologygeographic atrophyglaucoma

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Emmecell Comparables

Compare Emmecell with similar companies based on industry and business-model similarity.

Emmecell comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Trefoil Therapeutics
81%
ActualEyes, Inc.
80%
Cellusion Inc.
80%

Emmecell Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
StrategicJun 16, 2026
Series AJan 19, 2026

Key People

Founding team and executive leadership

Ramin Valian

Chief Executive Officer

Executive Team

Cyril Allouche

Chief Financial Officer & Treasurer

Executive Team

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 25, 2026

    Monthly visitors grew 101% MoM, reaching 3.2K.

  • Jan 23, 2026

    Monthly visitors grew 71% MoM, reaching 2.2K.

Recent news

Latest coverage and updates

  • recognized_asJul 13, 2026

    Emmecell recognized as FDA Regenerative Medicine Advanced Therapy (RMAT) designation for EO2002 on Jul 13th '26.

Emmecell Filings

Explore SEC and related filing metadata, where available.

Emmecell filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Emmecell's valuation, stock price, and market status.

Is Emmecell a public or private company?

Emmecell is a private company.

What is the current stock price of Emmecell?

Emmecell is a private company with no public stock price. No recent secondary market data is available.

How much is Emmecell worth (valuation)?

Valuation information for Emmecell is not publicly available.

Can I buy Emmecell stock?

Emmecell shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Emmecell's last funding round?

Funding round information for Emmecell is not publicly available.

Who are the main investors in Emmecell?

Investor information for Emmecell is not publicly disclosed.

Will Emmecell IPO soon?

No public IPO plans have been announced for Emmecell.

How can I track Emmecell secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Emmecell's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersMenlo Park, California
Employee Range10
Year Founded2012
Last FundingJun 16, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?